{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"25"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"34"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}]}],"title":"CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"425"}],"units":"Participants"}],"description":"Response was assessed according to IMWG criteria based on IRC assessment. Best response included PR, VGPR and CR. PR= \\>=50% reduction of serum M protein and \\>=90% or \\<200 mg reduction urinary M protein in 24-hour, or \\>50% decrease in difference between involved and uninvolved FLC levels, or \\>50% reduction in bone marrow plasma cells, if bone marrow plasma cells \\>30% and \\>50% reduction in size of soft tissue plasmacytomas at baseline. VGPR= \\>90% reduction (\\<100 mg/24-hour) in serum M-protein + urine M-protein detectable by immunofixation but not on electrophoresis. Complete response= \\>5% plasma cells in myelogram with absence of paraprotein in serum and urine according to immunofixation.","groups":[{"description":"Ixazomib placebo-matching capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized and had post-randomization data. The percentages are rounded off to the single nearest decimal point.","reportingStatus":"POSTED","timeFrame":"Up to 27 months","title":"Percentage of Participants Who Achieve or Maintain Any Best Response Category During the Treatment Period","type":"SECONDARY","unitOfMeasure":"percentage of participants"}